Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will announce its fourth quarter and full ...
Beam Therapeutics recently announced that it secured a standby license with Kobe University and Bio Palette for key gene-editing patents and confirmed the upcoming resignation of board member Carole ...
Beam Therapeutics (NASDAQ:BEAM) is one of the 17 biotechnology stocks with more than 50% upside. On January 22, Patrick Trucchio from H.C. Wainwright maintained a Buy rating on Beam Therapeutics ...
Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the 13 hot stocks to buy with the highest upside potential. On February 9, ...
Investor's Business Daily on MSN
Beam Therapeutics meets 80-plus relative strength rating benchmark
Beam Therapeutics sees its Relative Strength Rating reach the 80-plus level.
Charles Schwab Investment Management Inc. boosted its position in Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 3.1% during the 4th quarter, Holdings Channel.com reports. The institutional ...
Beam Global's CEO Desmond Wheatley is participating in two prominent investment conferences, enhancing the company's visibility among investors. The engagement offers one-on-one meeting opportunities ...
New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results